Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:02 PM ET

Life Sciences Tools and Services

Company Overview of BioAtla, LLC

Company Overview

BioAtla, LLC, a global biology outsourcing services provider, offers protein therapeutics technology and services. It provides target discovery services; and antibody evolution, engineering, and generation services that include antibody affinity maturation and functional engineering, antibody expression and purification, assay development and functional characterization, antibody internalization, antigen expression and purification, monoclonal and polyclonal antibody production, and follow-on biologics services. The company also offers Versitope system that maximizes epitope coverage, affinity, and functionality to deliver the path to discovery of immunization-induced antibodies; GigaMab, a ...

11011 Torreyana Road

San Diego, CA 92121

United States

Founded in 2007





Key Executives for BioAtla, LLC

Chairman, Chief Executive Officer, and President
Age: 57
Founder and Business Advisor
Age: 53
Vice President of Scientific Projects & Collaboration
Vice President of Scientific Projects & Collaboration
Compensation as of Fiscal Year 2015.

BioAtla, LLC Key Developments

BioAtla Announces Agreement with BioDuro to Collaborate on the Development of Two Therapeutic Monoclonal Antibodies in China

BioAtla announced an agreement with BioDuro to collaborate on the development of two therapeutic monoclonal antibodies in China. The two novel antibodies target specific indications with combined addressable populations of millions of patients. Under the terms of the agreement, BioAtla will direct BioDuro's efforts to advance these compounds through the preclinical and Phase I clinical phases. Under the direction of BioAtla, each candidate will be licensed to local Chinese biopharmaceutical companies for later stage clinical development and commercialization in China. The two compounds to be developed within the agreement target undisclosed indications. The objectives of the programs are to provide treatments that significantly improve the therapeutic result and safety compared to currently available therapies and that make important contributions to the containment of health care costs in China.

BioAtla, LLC Completes Engineering of Telephus Medical Antibody TPH 101 for Prevention of Infection in Septic Revision Hip and Knee Arthroplasty

BioAtla, LLC announced that BioAtla has successfully completed a key protein engineering phase of Telephus' compound TPH 101. TPH 101 is Telephus' lead program focused on the development of neutralizing antibodies targeting a key bacterial enzyme that drives the formation of antibiotic-resistant biofilm infections on implanted medical devices. BioAtla's proprietary Comprehensive Integrated Antibody Optimization (CIAO!(TM)) platform integrates important features of manufacturing and process development into protein design yielding superior antibody candidates. TPH 101 is designed to prevent devastating orthopedic periprosthetic joint infections and accompanying implant-associated osteomyelitis that can occur in total hip and knee replacement and other arthroplasty procedures. These infections can be medically and financially devastating to patients, with treatment costs that can be 4-6 times the cost of the original operation alone. There are approximately 1.05 million total hip and knee replacement procedures performed annually in the United States today, with those procedures projected to cost nearly $120 billion by 2020. Treatment of periprosthetic joint infections in some patients who undergo these procedures is projected to cost the healthcare system $1.7 billion in that same year.

BioAtla, LLC Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014

BioAtla, LLC Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014 . Venue: Westin San Francisco Market Street, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
Regenerative Medicine Foundation United States
SensiQ Technologies, Inc. United States
DPT Lakewood, Inc. United States
InKaryo Corporation United States
Vascudyne, Inc. United States

Recent Private Companies Transactions

Private Placement
March 21, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioAtla, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at